Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative biologic therapies for treating solid tumors and chemotherapy-induced peripheral neuropathy (CIPN). Their lead candidate, BXQ-350, is a first-in-class biologic that modulates sphingolipid metabolism to target metastatic cancers and address neuropathic pain, with promising safety and efficacy data from clinical trials. The company aims to improve survival and quality of life for cancer patients through its novel therapeutics and is actively engaged in clinical research, including Phase 1b/2 trials and scientific presentations at major oncology conferences.
Industries
Nr. of Employees
small (1-50)
Bexion Pharmaceuticals, Inc.
632 Russell Street, Covington, KY 41011
Patents
Products
Investigational sphingolipid-modulating biologic (protein-containing lipid nanovesicle)
An investigational biologic formulated as protein-containing phospholipid vesicles that modulates sphingolipid metabolism by activating enzymes to increase ceramides and lower sphingosine-1-phosphate; evaluated in preclinical models and early-phase clinical trials for solid tumors and CIPN.
Investigational sphingolipid-modulating biologic (protein-containing lipid nanovesicle)
An investigational biologic formulated as protein-containing phospholipid vesicles that modulates sphingolipid metabolism by activating enzymes to increase ceramides and lower sphingosine-1-phosphate; evaluated in preclinical models and early-phase clinical trials for solid tumors and CIPN.
Services
Design and conduct of early-phase oncology and pediatric clinical trials, including enrollment management and data collection for safety and efficacy endpoints.
In vitro and in vivo preclinical studies including neuronal cytoprotection assays, murine CIPN models, antiviral screening and translational biomarker analysis.
Pre-formulation, formulation development and drug product scale-up for protein-based lipid vesicle biologics.
Design and execution of biomarker-driven translational studies linking sphingolipid pathway modulation to clinical and preclinical endpoints.
Design and conduct of early-phase oncology and pediatric clinical trials, including enrollment management and data collection for safety and efficacy endpoints.
In vitro and in vivo preclinical studies including neuronal cytoprotection assays, murine CIPN models, antiviral screening and translational biomarker analysis.
Pre-formulation, formulation development and drug product scale-up for protein-based lipid vesicle biologics.
Design and execution of biomarker-driven translational studies linking sphingolipid pathway modulation to clinical and preclinical endpoints.
Expertise Areas
- Clinical trial management (Phase 1–2, pediatric)
- Oncology drug development (solid tumors)
- Chemotherapy-induced peripheral neuropathy (CIPN) research
- Translational pharmacology and biomarker development
Key Technologies
- Nanovesicle lipid formulation
- Saposin C-mediated sphingolipid activation
- Sphingolipid biomarker analysis (S1P, ceramide)
- High-content neuronal imaging assays
News & Updates
Bexion Pharmaceuticals announced participation in the Jefferies London Healthcare Conference scheduled for November 19-21, 2024, in London, UK, with key executives attending.
The company announced the completion of enrollment in the open-label portion of its Phase 1b/2 trial evaluating BXQ-350 in combination with standard care for metastatic colorectal cancer.
Bexion announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, focusing on BXQ-350's immune response rebalancing approach.
The company received a grant to support the development of BXQ-350, highlighting its potential in neurodegenerative and neuropathic conditions.
An article providing statistics on colorectal cancer, including incidence, mortality, and survival rates.
An article discussing care strategies for children with diffuse midline glioma.
Bexion Pharmaceuticals announced participation in the Jefferies London Healthcare Conference scheduled for November 19-21, 2024, in London, UK, with key executives attending.
The company announced the completion of enrollment in the open-label portion of its Phase 1b/2 trial evaluating BXQ-350 in combination with standard care for metastatic colorectal cancer.
Bexion announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, focusing on BXQ-350's immune response rebalancing approach.
The company received a grant to support the development of BXQ-350, highlighting its potential in neurodegenerative and neuropathic conditions.
An article providing statistics on colorectal cancer, including incidence, mortality, and survival rates.
An article discussing care strategies for children with diffuse midline glioma.